These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Müller T; Kolf K; Ander L; Woitalla D; Muhlack S Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980 [TBL] [Abstract][Full Text] [Related]
92. Clinical advantages of COMT inhibition with entacapone - a review. Gordin A; Kaakkola S; Teräväinen H J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869 [TBL] [Abstract][Full Text] [Related]
93. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897 [TBL] [Abstract][Full Text] [Related]
94. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy. Annus Á; Vécsei L Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288 [TBL] [Abstract][Full Text] [Related]
95. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536 [TBL] [Abstract][Full Text] [Related]
96. The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease. Lyytinen J; Kaakkola S; Gordin A; Kultalahti ER; Teräväinen H; Sovijärvi A Parkinsonism Relat Disord; 2002 Jun; 8(5):349-55. PubMed ID: 15177064 [TBL] [Abstract][Full Text] [Related]
97. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Hoda F; Nicholl D; Bennett P; Arranz M; Aitchison KJ; al-Chalabi A; Kunugi H; Vallada H; Leigh PN; Chaudhuri KR; Collier DA Biochem Biophys Res Commun; 1996 Nov; 228(3):780-4. PubMed ID: 8941353 [TBL] [Abstract][Full Text] [Related]
98. More than an "inverted-U"? An exploratory study of the association between the catechol-o-methyltransferase gene polymorphism and executive functions in Parkinson's disease. Fang YJ; Tan CH; Tu SC; Liu CY; Yu RL PLoS One; 2019; 14(3):e0214146. PubMed ID: 30897147 [TBL] [Abstract][Full Text] [Related]
99. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. Jost WH; Kupsch A; Mengs J; Delf M; Bosse D Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650 [TBL] [Abstract][Full Text] [Related]
100. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Syvänen AC; Tilgmann C; Rinne J; Ulmanen I Pharmacogenetics; 1997 Feb; 7(1):65-71. PubMed ID: 9110364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]